18F-DCFPyl PET Imaging for Prostate Cancer
Trial Summary
What is the purpose of this trial?
The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate cancer when comparing to 68Ga-PSMA-11 PET/CT (another type of diagnostic scan for prostate cancer).
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
What data supports the effectiveness of the drug 18F-DCFPyL for prostate cancer?
Is 18F-DCFPyL PET imaging safe for humans?
How does 18F-DCFPyL PET imaging differ from other prostate cancer treatments?
18F-DCFPyL PET imaging is unique because it uses a radiotracer that specifically targets the prostate-specific membrane antigen (PSMA), allowing for more accurate detection and localization of prostate cancer lesions compared to conventional imaging methods. This can lead to changes in patient management, as it often identifies cancer that other scans miss.34567
Research Team
Heather Jacene
Principal Investigator
Dana-Farber Cancer Institute
Eligibility Criteria
This trial is for adults with confirmed prostate cancer who are set to receive standard 177Lu-Vipivotide Tetraxetan therapy. They must have shown a positive response on a previous diagnostic scan and be willing to use birth control. People with severe illnesses, allergies to similar drugs, or conditions that could affect the study's outcome can't participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Imaging
Baseline screening visit with PSMA-PET/CT scan with Ga-PSMA-11
Diagnostic Imaging
In-clinic visit with exam and PSMA-PET/CT scan with 18F-DCFPyl per standard institutional procedures
Standard of Care Therapy
Participants receive standard of care therapy
Follow-up
Follow up every 3 months via chart review for 12 months, with the purpose of seeing how participants respond to 177Lu-vipivotide tetraxetan treatment
Treatment Details
Interventions
- 18F-DCFPyL
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor
Brigham and Women's Hospital
Lead Sponsor
Progenics Pharmaceuticals, Inc.
Industry Sponsor